Dark

TCRX
TScan Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open

May 9, 2025 1:42:29 PM EDT

1.34USD-2.899%(-0.04)107,859

1.34Bid 1.35Ask 0.01Spread

Pre-market

May 6, 2025 9:12:30 AM EDT

1.51USD+9.420%(+0.13)0

After-hours

May 8, 2025 4:00:30 PM EDT

1.38USD+0.364%(+0.01)0

Overview HistoricalExchangesShortsNews

Jan 24, 2022

07:08AM EST TScan Therapeutics Announces the FDA Has Cleared its Investigational New Drug Application to Evaluate TSC-100 for the Treatment of Patients with Hematologic Malignancies, Expects to Begin Dosing Patients in 1H 2022 Benzinga

07:00AM EST Phase 1 trial of TSC-100 expected to initiate in the first half of 2022 GlobeNewswire Inc

Jan 10, 2022

07:00AM EST IND Submissions Completed in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Candidates TSC-100 and TSC-101 GlobeNewswire Inc

Dec 16, 2021

10:14AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021 Benzinga

06:15AM EST HC Wainwright & Co. Initiates Coverage On TScan Therapeutics with Buy Rating, Announces Price Target of $21 Benzinga

Dec 13, 2021

09:20AM EST TScan Therapeutics Announces Poster Presentations At 63rd American Society Of Hematology Annual Meeting And Exposition Benzinga

09:16AM EST - Posters highlight discovery of TSC-101, manufacturing process and clinical development plan for liquid tumor candidates TSC-101 and TSC-102 - GlobeNewswire Inc

Dec 3, 2021

07:00AM EST TScan Therapeutics to Host a Virtual Event to Discuss Highlights GlobeNewswire Inc

Dec 2, 2021

07:00AM EST TScan Therapeutics Establishes Facility to Manufacture T Cell GlobeNewswire Inc

Nov 11, 2021

07:00AM EST TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate virtually at the following upcoming investor conferences: GlobeNewswire Inc

Nov 10, 2021

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

07:53AM EST TScan Therapeutics Q3 Net Loss $15.8 Mln Or $0.80/Shr Vs Loss Of $7.2 Mln Or $7.16/Shr Last Year RTTNews

07:15AM EST TScan Therapeutics Q3 EPS $(0.80) Up From $(7.16) YoY, Sales $2.41M Up From $290.00K YoY Benzinga

07:00AM EST IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates TSC-100 and TSC-101 GlobeNewswire Inc

Oct 5, 2021

07:09AM EDT TScan Therapeutics Appoints Heather Savelle As VP, Investor Relations RTTNews

07:00AM EDT TScan Therapeutics Appoints Heather Savelle as Vice President, GlobeNewswire Inc

Sep 28, 2021

07:27AM EDT TScan Therapeutics To Participate In Chardan 5th Annual Genetic Medicines Conference Oct. 5 Benzinga

07:00AM EDT TScan Therapeutics to Participate in the Chardan 5th Annual GlobeNewswire Inc

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 16, 2021

07:48AM EDT The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study Benzinga

Sep 15, 2021

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

Sep 14, 2021

07:50AM EDT The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout Benzinga

Sep 10, 2021

08:00AM EDT The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test Benzinga

Sep 9, 2021

04:05PM EDT TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that Zoran Zdraveski, J.D., Ph.D. has been appointed as Chief Legal Officer. GlobeNewswire Inc

Sep 2, 2021

07:00AM EDT TScan Therapeutics to Participate in the Morgan Stanley 19th GlobeNewswire Inc

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 27, 2021

07:35AM EDT The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration Benzinga

Aug 26, 2021

08:09AM EDT The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

07:08AM EDT TScan Therapeutics Q2 EPS $(7.69) Down From $(6.18) YoY, Sales $2.85M Benzinga

07:00AM EDT Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs GlobeNewswire Inc

Aug 13, 2021

10:11AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 13, 2021 Benzinga

05:59AM EDT Cowen & Co. Initiates Coverage On TScan Therapeutics with Outperform Rating Benzinga

Aug 10, 2021

10:32AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2021 Benzinga

06:05AM EDT Morgan Stanley Initiates Coverage On TScan Therapeutics with Overweight Rating, Announces Price Target of $22 Benzinga

05:33AM EDT Jefferies Initiates Coverage On TScan Therapeutics with Buy Rating, Announces Price Target of $21 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 23, 2021

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 21, 2021

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

07:06AM EDT TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious Disease Summit Benzinga

07:00AM EDT TScan Therapeutics to Present Discovery of T Cell Targets for GlobeNewswire Inc

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

11:36AM EDT TScan Therapeutics Shares Open For Trade At $12; IPO Priced At $15/Share Benzinga

09:55AM EDT TScan Therapeutics Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade after 10:20 a.m. EDT; IPO Priced At $15/Share Benzinga

Jul 15, 2021

07:01PM EDT TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering GlobeNewswire Inc